Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes

Observational Study on Safety and Efficacy in Subjects Using NovoMix® 70 (Biphasic Insulin Aspart) for Treatment of Type 2 Diabetes Mellitus

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.

Inclusion Criteria:

• Type 2 diabetes
• HbA1c over 7%
• No contraindication with NovoMix® 70

Exclusion Criteria:

• Type 1 diabetes
• Subjects participating in a clinical trial or another observational study
• Subjects under previous basis-bolus insulin therapy
• Women who are pregnant, breast feeding and women of child bearing capacity who are not using any reliable contraceptive method